Alyeska Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.9M | Sell |
65,000
-366,804
| -85% | -$163M | 0.1% | 229 |
|
|
2025
Q1 | $209M | Buy |
431,804
+354,269
| +457% | +$172M | 0.83% | 19 |
|
|
2024
Q4 | $31.2M | Buy |
77,535
+74,182
| +2,212% | +$29.9M | 0.12% | 207 |
|
|
2024
Q3 | $1.56M | Buy |
+3,353
| New | +$1.56M | 0.01% | 436 |
|
|
2023
Q3 | – | Sell |
-162,049
| Closed | -$57M | – | 611 |
|
|
2023
Q2 | $57M | Buy |
+162,049
| New | +$57M | 0.42% | 75 |
|
|
2021
Q2 | – | Sell |
-95,881
| Closed | -$20.6M | – | 843 |
|
|
2021
Q1 | $20.6M | Buy |
+95,881
| New | +$20.6M | 0.27% | 110 |
|
|
2019
Q3 | – | Sell |
-3,811
| Closed | -$699K | – | 471 |
|
|
2019
Q2 | $699K | Buy |
+3,811
| New | +$699K | 0.01% | 352 |
|
|
2017
Q3 | – | Sell |
-7,503
| Closed | -$967K | – | 512 |
|
|
2017
Q2 | $967K | Sell |
7,503
-112,686
| -94% | -$14.5M | 0.01% | 393 |
|
|
2017
Q1 | $13.1M | Sell |
120,189
-101,845
| -46% | -$11.1M | 0.11% | 231 |
|
|
2016
Q4 | $16.4M | Buy |
222,034
+97,034
| +78% | +$7.15M | 0.14% | 228 |
|
|
2016
Q3 | $10.9M | Buy |
+125,000
| New | +$10.9M | 0.1% | 250 |
|
|
2016
Q1 | – | Sell |
-269,490
| Closed | -$33.9M | – | 443 |
|
|
2015
Q4 | $33.9M | Sell |
269,490
-133,865
| -33% | -$16.8M | 0.36% | 113 |
|
|
2015
Q3 | $42M | Buy |
403,355
+252,575
| +168% | +$26.3M | 0.49% | 71 |
|
|
2015
Q2 | $18.6M | Sell |
150,780
-8,708
| -5% | -$1.08M | 0.21% | 154 |
|
|
2015
Q1 | $18.8M | Buy |
159,488
+8,020
| +5% | +$946K | 0.26% | 144 |
|
|
2014
Q4 | $18M | Buy |
151,468
+107,718
| +246% | +$12.8M | 0.31% | 112 |
|
|
2014
Q3 | $4.91M | Buy |
+43,750
| New | +$4.91M | 0.1% | 213 |
|
|
2013
Q3 | – | Sell |
-85,000
| Closed | -$6.81M | – | 301 |
|
|
2013
Q2 | $6.81M | Buy |
+85,000
| New | +$6.81M | 0.33% | 80 |
|